Publications by authors named "A C Paulino"
Background: In the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II-IV FAWT. Four-year event-free survival (EFS) and overall survival (OS) for stage I FAWT were 67.5% and 88.
View Article and Find Full Text PDFPurpose: National Wilms Tumor Study-5 (NWTS-5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT).
Patients And Methods: Eligible patients with RTK were enrolled prospectively on NWTS-5 (1995-2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005-2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH-1 or dose-reduced Revised UH-1).
Osteoradionecrosis in Pediatric Patients Treated with Proton Therapy for Head and Neck Malignancies.
Int J Radiat Oncol Biol Phys
December 2024
Purpose: Osteoradionecrosis (ORN) is a feared complication after head and neck radiation, but the incidence and radiotherapy risk factors for ORN in children are unknown. In this retrospective analysis of a prospectively collected dataset, we evaluated the incidence and factors associated with development of ORN in children treated with proton therapy for head and neck malignancies.
Methods And Materials: We reviewed records from patients treated at a single institution between December 2006 and February 2020 including demographic data, tumor, and treatment details, ORN occurrence, and dosimetry.
Copaifera sp. is a native tree in the Amazon region. Copaiba oleoresin has components such as sesquiterpenes, which have anti-inflammatory and antioxidant potential.
View Article and Find Full Text PDFArticle Synopsis
- Despite significant improvements in the cure rate of childhood cancer over recent decades, survivors often face late effects, particularly from radiotherapy.
- Recent strategies aim to reduce or eliminate radiotherapy in children who respond well to chemotherapy, as seen in conditions like Hodgkin lymphoma and certain Wilms tumors.
- Innovations like molecular subtyping in medulloblastoma and targeted dose escalation in rhabdomyosarcoma and Ewing sarcoma are being explored to enhance treatment outcomes while minimizing late toxicity.